Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on February 23, 2006:
- Previous Holdings: 17,798,717 Ordinary Share ADRs
- New Holdings: 17,709,339 Ordinary Share ADRs
- Net Change: Decrease of 89,378 ADRs
- Average Price: $51.32
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R (1) (b).
Key Facts for Investor Verification
- Verify the impact of the 89,378 ADR reduction on the total beneficial ownership of the US Retirement Savings Plan.
- Confirm the specific beneficial ownership percentages of Directors Dr. J P Garnier and Dr. T Yamada relative to the fund's holdings.
- Review the fund movement details on February 23, 2006, to understand the driver behind the share reduction.